NASDAQ · Financial Statements

Azora Therapeutics, Inc. (AZR) Revenue, Earnings & Financial Statements

$3.81 NASDAQ: AZR Market Cap $10.00M

Data as of Nov 16, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Azora Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $8.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Income Statement — 1 Years (USD millions)

Metric2025
Revenue$0
Operating Expenses$8.0M
Operating Profit−$8.0M
Other Income$0
Interest$0
Depreciation$0
Profit Before Tax−$8.0M
Tax rate (%)0.0%
Net Profit−$8.0M
EPS−$11.93

Quarterly Results — Last 4 Quarters (USD millions)

MetricDec '25Mar '26Jun '26Sep '26
Revenue$0$0$0$0
Operating Expenses$2.0M$2.0M$52.0M$8.0M
Operating Profit−$2.0M−$2.0M−$52.0M−$8.0M
Interest$0$0$0$0
Profit Before Tax−$2.0M−$2.0M−$52.0M−$65.0M
Tax rate (%)0.0%0.0%0.0%0.0%
Net Profit−$2.0M−$2.0M−$52.0M−$65.0M
EPS−$1.80−$1.48−$11.25−$4.52

Balance Sheet — 1 Years (USD millions)

Metric2025
Total Assets$7.0M
Current Assets$6.0M
Cash$6.0M
Inventory$0
Receivables$0
Fixed Assets$0
Capital Work in Progress$0
Investments$0
Other Assets$0
Total Liabilities$2.0M
Current Liabilities$1.0M
Borrowings$0
Other Liabilities$2.0M
Equity$0
Reserves$5.0M

For Azora Therapeutics, Inc., operating cash flow was positive in 0 of 9 reported years; free cash flow in the latest year was negative at $6.0M; free cash flow was positive in 0 of 9 years.

Cash Flow Statement — 9 Years (USD millions)

Metric201720182019202020212022202320242025
Operating Cash Flow$0−$2.0M−$6.0M−$8.0M−$12.0M−$11.0M−$7.0M−$7.0M−$6.0M
Investing Cash Flow$0——$0$0—$2.0M—$0
Financing Cash Flow$0$6.0M$9.0M$6.0M$14.0M$9.0M$4.0M$8.0M$8.0M
Net Cash Flow$0$4.0M$3.0M−$2.0M$2.0M−$2.0M−$1.0M$1.0M$2.0M
Free Cash Flow$0−$2.0M−$6.0M−$8.0M−$12.0M−$11.0M−$7.0M−$7.0M−$6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.16
FCF Yield-92.95%
Quick Ratio4.43
Interest Coverage—
Return 1Y-53.82%
Return 3Y-92.74%
Return 5Y-99.82%

Azora Therapeutics, Inc. (AZR) financials — frequently asked questions

What is Azora Therapeutics, Inc.'s annual revenue?

Azora Therapeutics, Inc. (AZR) reported annual revenue of $0 in its most recent fiscal year.

What is Azora Therapeutics, Inc.'s net profit?

Azora Therapeutics, Inc. (AZR) reported a net loss of $8.0M in its most recent fiscal year.

What is AZR EV/EBITDA?

Azora Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -0.16. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Medical - Pharmaceuticals stocks

RPRX revenue $2.4BCORT revenue $761.0MLQDA revenue $158.0MPBH revenue $1.1BQUIT financialsHITI revenue $594.0MTRXB stockAll Medical - Pharmaceuticals stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
AZR Overview AZR Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.